Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axon Enterprise Inc (AXON) vs Cassava Sciences Inc (FLNA) Price & Performance

Axon Enterprise IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Axon Enterprise Inc vs Cassava Sciences Inc — how do they compare? Axon Enterprise Inc trades at $616.91 (market cap $51.69B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Axon Enterprise Inc is far larger — about 1082.5× Cassava Sciences Inc's market cap, and Axon Enterprise Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AXONFLNA
Market Cap
$51.69B$47.75M
Sector
TechnologyHealth
52-Week High
$791.62$4.64
52-Week Low
$345.94$0.87
Enterprise Value
$52.83B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axon Enterprise Inc

Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.

Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.

Read more on AXON

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA